PHARMACEUTICAL companies are planning to bring forward more than 50 major submissions for consideration at the Pharmaceutical Benefits Advisory Committee's (PBAC) meeting in Mar 2025.
The Department of Health and Aged Care said this is an unprecedented number, and exceeds both the current capacity of the contracted Health Technology Assessment workforce for evaluation, and the number the PBAC can consider in one meeting.
As a result, the Department has carefully selected which submissions will be addressed by the PBA in Mar, and which will be held over until the Jul 2025 meeting.
The affected pharmaceutical companies, and Medicines Australia, have been contacted by the Department.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Oct 24
